News coverage about Neurometrix (NASDAQ:NURO) has been trending somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neurometrix earned a news impact score of 0.18 on Accern’s scale. Accern also assigned media headlines about the medical device company an impact score of 46.8324008400398 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of Neurometrix (NASDAQ:NURO) traded up $0.06 on Wednesday, hitting $1.40. The stock had a trading volume of 461,300 shares, compared to its average volume of 1,292,696. The stock has a market cap of $3.14, a PE ratio of -0.08 and a beta of 0.21. Neurometrix has a twelve month low of $1.20 and a twelve month high of $6.08.

A number of research analysts recently commented on the company. ValuEngine raised Neurometrix from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. HC Wainwright reissued a “buy” rating and issued a $3.00 price target (down from $10.00) on shares of Neurometrix in a report on Friday, October 20th. Finally, Zacks Investment Research cut Neurometrix from a “hold” rating to a “sell” rating in a report on Wednesday, January 24th.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at

Neurometrix Company Profile

NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.

Insider Buying and Selling by Quarter for Neurometrix (NASDAQ:NURO)

Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with's FREE daily email newsletter.